Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase

The p38 MAP kinase is implicated in the release of the pro-inflammatory cytokines TNFα and IL-1b. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn’s disease. A new lead structure for p38 MAP kinase inhibition was identified. Herein, we report the SAR of this new class of p38 inhibitors.

Heterocyclic 2-amides were identified as novel lead structures for p38 MAP kinase inhibition, and a SAR analysis of 25 compounds was executed.Figure optionsDownload as PowerPoint slide